News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
818,003 Results
Type
Article (74456)
Company Profile (644)
Press Release (742903)
Multimedia
Podcasts (126)
Webinars (14)
Section
Business (227519)
Career Advice (3721)
Deals (39311)
Drug Delivery (129)
Drug Development (89367)
Employer Resources (198)
FDA (17867)
Job Trends (17142)
News (387842)
Policy (38781)
Tag
Academia (2999)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (96)
Alliances (55993)
ALS (104)
Alzheimer's disease (1505)
Antibody-drug conjugate (ADC) (164)
Approvals (17822)
Artificial intelligence (309)
Autoimmune disease (29)
Automation (16)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (440)
Bladder cancer (85)
Brain cancer (32)
Breast cancer (313)
Cancer (2482)
Cardiovascular disease (210)
Career advice (3170)
Career pathing (34)
CAR-T (176)
Cell therapy (491)
Cervical cancer (22)
Clinical research (72282)
Collaboration (935)
Company closure (2)
Compensation (578)
Complete response letters (30)
COVID-19 (2868)
CRISPR (50)
C-suite (275)
Cystic fibrosis (109)
Data (2361)
Decentralized trials (2)
Denatured (43)
Depression (56)
Diabetes (302)
Diagnostics (6924)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (132)
Drug pricing (130)
Drug shortages (33)
Duchenne muscular dystrophy (104)
Earnings (94264)
Editorial (47)
Employer branding (25)
Employer resources (167)
Events (129103)
Executive appointments (788)
FDA (19296)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (826)
Gene editing (125)
Generative AI (28)
Gene therapy (363)
GLP-1 (860)
Government (5121)
Grass and pollen (6)
Guidances (150)
Healthcare (20874)
Huntington's disease (26)
IgA nephropathy (31)
Immunology and inflammation (152)
Indications (30)
Infectious disease (3031)
Inflammatory bowel disease (159)
Inflation Reduction Act (11)
Influenza (58)
Intellectual property (102)
Interviews (727)
IPO (17760)
IRA (51)
Job creations (4992)
Job search strategy (2593)
Kidney cancer (11)
Labor market (47)
Layoffs (564)
Leadership (24)
Legal (9916)
Liver cancer (82)
Lung cancer (349)
Lymphoma (161)
Machine learning (9)
Management (65)
Manufacturing (364)
MASH (81)
Medical device (14624)
Medtech (14629)
Mergers & acquisitions (22118)
Metabolic disorders (806)
Multiple sclerosis (89)
NASH (23)
Neurodegenerative disease (116)
Neuropsychiatric disorders (34)
Neuroscience (2120)
NextGen: Class of 2025 (7635)
Non-profit (5080)
Now hiring (41)
Obesity (433)
Opinion (275)
Ovarian cancer (83)
Pain (105)
Pancreatic cancer (91)
Parkinson's disease (162)
Partnered (22)
Patents (258)
Patient recruitment (119)
Peanut (51)
People (64126)
Pharmaceutical (133)
Pharmacy benefit managers (22)
Phase I (22340)
Phase II (31533)
Phase III (23767)
Pipeline (1397)
Policy (180)
Postmarket research (3256)
Preclinical (9865)
Press Release (72)
Prostate cancer (114)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (436)
Real estate (7146)
Recruiting (75)
Regulatory (26114)
Reports (58)
Research institute (2655)
Resumes & cover letters (579)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (82)
Series A (144)
Series B (94)
Service/supplier (26)
Sickle cell disease (59)
Special edition (20)
Spinal muscular atrophy (165)
Sponsored (34)
Startups (4201)
State (2)
Stomach cancer (16)
Supply chain (75)
Tariffs (54)
The Weekly (81)
Vaccines (822)
Venture capitalists (45)
Weight loss (306)
Women's health (39)
Worklife (20)
Date
Last 7 days (987)
Last 30 days (3183)
Last 365 days (34891)
2025 (12560)
2024 (37898)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57663)
2019 (51302)
2018 (39084)
2017 (36831)
2016 (37739)
2015 (43731)
2014 (38413)
2013 (34391)
2012 (36287)
2011 (36403)
2010 (35833)
Location
Africa (1191)
Alabama (61)
Alaska (7)
Arizona (249)
Arkansas (14)
Asia (48690)
Australia (8369)
California (6679)
Canada (2107)
China (574)
Colorado (289)
Connecticut (305)
Delaware (166)
Europe (110024)
Florida (977)
Georgia (226)
Hawaii (1)
Idaho (63)
Illinois (623)
India (30)
Indiana (342)
Iowa (12)
Japan (177)
Kansas (112)
Kentucky (28)
Louisiana (15)
Maine (70)
Maryland (992)
Massachusetts (5107)
Michigan (250)
Minnesota (430)
Mississippi (2)
Missouri (92)
Montana (31)
Nebraska (26)
Nevada (69)
New Hampshire (69)
New Jersey (1878)
New Mexico (31)
New York (1876)
North Carolina (1142)
North Dakota (9)
Northern California (2877)
Ohio (224)
Oklahoma (15)
Oregon (46)
Pennsylvania (1463)
Puerto Rico (14)
Rhode Island (36)
South America (1565)
South Carolina (26)
South Dakota (1)
Southern California (2482)
Tennessee (108)
Texas (995)
United States (25443)
Utah (199)
Virginia (175)
Washington D.C. (72)
Washington State (611)
West Virginia (3)
Wisconsin (70)
818,003 Results for "guangzhou xiangxue pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
March 25, 2025
·
5 min read
Press Releases
AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Completion of Sample Set for the Strategic Partnership Implemented to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration
May 9, 2025
·
3 min read
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Press Releases
Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan
December 25, 2024
·
1 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
Press Releases
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025
March 31, 2025
·
12 min read
1 of 81,801
Next
